A series of new appointments In-PharmaTechnologistcom provides a round-up – People on the move
technology sector, with a series of new appointments.
In-PharmaTechnologist.com provides a round-up.
Linda Harty has been appointed senior vice president and treasurer at Cardinal Health, reporting to chief financial officer Michael Losh. She was formerly CFO of the RTM Restaurant group, and replaces Donna Brandin, who left Cardinal in July 2004.
UK-based separations company Whatman - fresh from a round of staffing cuts in the wake of its acquisition of Germany's Schleicher & Schuell - has named Thomas McNally, an existing non-executive director of the company, as vice chairman. It has also appointed Dr Hinrich Kehler as a non-executive director.
Chemical catalyst company Chiral Quest's management team has been boosted by the addition of Dr Michael Cannarsa as vice president of business development, Dr Chunhua Yang as director of process development and manufacturing and Dr Bing Yu as director of global operations.
Jonathan Youles has taken the position of sales director of milling, mixing, vacuum conveying and lifting company Ytron-Quadro (UK) Ltd. He was previously an area sales manager for Hosokawa Micron. Meanwhile, in a restructuring of top management positions, Paul Bradley has been appointed technical director of the company, while Alison Bridge continues in her role as financial director.
Dr Juergen Strube, chairman of German chemicals giant BASF, to be awarded the 2005 International Palladium medal by the Société de Chimie Industrielle-American Section, "in recognition of his many distinguished contributions to the chemical industry." He has worked at BASF since 1969.
Malgorzata Ciesiolka has joined the licensing department of Belgian pharmaceutical services company PSI, which recently became part of Indian active pharmaceutical ingredient (API) supplier Jubilant Organosys
Melanie Welham has become the first female ever to be appointed professor of pharmacy at the University of Bath in the UK. Prof Welham's research interests are in the signalling processes that control the growth and developmental of stem cells for use in future treatments for a range of diseases, including Alzheimer's and Parkinson's, and spinal cord injuries.
